155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT
K. Klinghammer, N.F. Saba, E. Castelluci, A.D. Colevas, T. Rutkowski, R. Greil, D. Thurner, U. Müller-Richter, Anna Maria Di Giacomo, Jyoti Grewal, C.H.H. Ottensmeier, A. Atasoy, S. Shpyro, P. Brück, J. Dias, C. Ganser, Ö. Türeci, U. Sahin
Abstract
BNT113 is an IV administered liposomal ribonucleic acid (RNA-LPX) cancer vaccine encoding the human papillomavirus (HPV)16 oncoproteins E6 and E7. Preclinically, PD-L1 inhibition augments the anti-tumor effect of RNA-LPX-based vaccines, supporting combining BNT113 + pembrolizumab.
Topics & Concepts
PembrolizumabMedicineOncologyInternal medicineCancerCancer researchImmunotherapyCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsProstate Cancer Treatment and Research